Minapharm Pharmaceuticals
🇪🇬Egypt
- Country
- 🇪🇬Egypt
- Ownership
- Public
- Established
- 1958-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.minapharm.com
Clinical Trials
7
Active:0
Completed:0
Trial Phases
1 Phases
Phase 4:7
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 4
7 (100.0%)Study to Assess the Safety & Efficacy of Oral Ciprodiazole Versus Currently Used Ciprofloxacin & Metronidazole
Phase 4
Recruiting
- Conditions
- Surgical Site Infections
- Interventions
- Drug: Ciprodiazole
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- MinaPharm Pharmaceuticals
- Target Recruit Count
- 312
- Registration Number
- NCT05863832
- Locations
- 🇪🇬
Faculty of Medicine - Menofia University, Shibīn Al Kawm, Menofia, Egypt
Study to Compare the Efficacy & Safety of Ursoplus Capsules vs. UDCA vs. Placebo Among Chronic Liver Disease Patients
Phase 4
Recruiting
- Conditions
- Chronic Liver Disease
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- MinaPharm Pharmaceuticals
- Target Recruit Count
- 297
- Registration Number
- NCT05849558
- Locations
- 🇪🇬
Air Force Specialized Hospital, Cairo, New Cairo, Egypt
Study Evaluation of Recombinant Hirudin in Prophylaxis of Post-Operative Deep Vein Thrombosis
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- MinaPharm Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT05847205
- Locations
- 🇪🇬
Alexandria University, Alexandria, Egypt
Gonapure® in Multifollicular Stimulation in Egyptian Women Undergoing IVF/ICSI
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2017-08-30
- Lead Sponsor
- MinaPharm Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT03057574
- Locations
- 🇪🇬
Alexandria University, Alexandria, Egypt
🇪🇬Ain Shams University, Cairo, Egypt
Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas
Phase 4
- Conditions
- r-Hirudin (Thrombexx) Efficacy in Treatment of Haematomas
- Interventions
- Drug: active product ( Thrombexx) assigned to arm 1Other: Placebo assigned to arm 2
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2013-10-10
- Lead Sponsor
- MinaPharm Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT01960569
- Locations
- 🇪🇬
Prof. Mahmoud Hafez, Cairo, Egypt
- Prev
- 1
- 2
- Next
News
No news found